A Phase 3 interventional study of Enicepatide and Placebo in Overweight, Obesity and Cardiovascular Disease, sponsored by Hoffmann-La Roche. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Obesity by Hoffmann-La Roche — 8 open to participants now, 12 under way, 7 of them phase 3. Obesity · Hoffmann-La Roche.
Among the 21 studies in Obesity by Hoffmann-La Roche, this one has the largest planned enrollment, is the only one that started in 2027, is one of 8 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 21st registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →8 of the 21 studies in Obesity by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in United States, Taiwan, United Kingdom
Ages 40+
Hoffmann-La Roche · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in China
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 19 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8,200 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 300 across the 21 interventional studies. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
3 of the studies in Obesity by Hoffmann-La Roche that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06982131Hoffmann-La RocheA Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants | 2026-12-07 |
| NCT07499050Hoffmann-La RocheA Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight | 2027-01-09 |
| NCT07589686Hoffmann-La RocheA Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight | 2027-11-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Obesity by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), as a therapy to reduce the risk of major adverse cardiovascular events (MACE) in adults living with overweight or obesity and established cardiovascular disease (CVD), with or without type 2 diabetes mellitus (T2DM).
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's planned enrollment of 8,200 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive volume-matched placebo.
Combination Product: Placebo
Participants will receive enicepatide.
Combination Product: Enicepatide
Participants will receive enicepatide as per the schedule described in the protocol.
Also known as: RO7795068, CT-388, RG6640
Participants will receive volume-matched placebo as per the schedule described in the protocol.
Time to First Occurrence of Any Component of 5-point (5P) MACE
The components of this composite 5P MACE endpoint consist of cardiovascular (CV) death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for heart failure (HHF) or urgent heart failure (HF) visit, or urgent coronary revascularization.
Time frame: From randomization up to 4.2 years
Time to First Occurrence of Any Component of 3-point (3P) MACE
The components of this composite 3P MACE endpoint consist of CV death, non-fatal MI or non-fatal stroke.
Time frame: From randomization up to 4.2 years
Time to New-Onset T2DM
Time frame: From randomization up to 4.2 years
Total Occurrence of All-Cause Hospitalization
Time frame: From randomization up to 4.2 years
Time to Death From Any Cause
Time frame: From randomization up to 4.2 years
Time to CV Death
Time frame: From randomization up to 4.2 years
Incidence and Severity of Adverse Events
Time frame: From baseline up to 4.2 years
Time to First Occurrence of Any Component of 4-point (4P) MACE
The components of this composite 4P MACE endpoint consist of CV death, non-fatal MI, non-fatal stroke, or HHF or urgent HF visit.
Time frame: From randomization up to 4.2 years
Time to First Occurrence of HHF, Urgent HF Visit, or CV Death
Time frame: From randomization up to 4.2 years
Time to First Occurrence of HHF, Urgent HF Visit, or All-Cause Mortality
Time frame: From randomization up to 4.2 years
Change From Baseline in Health-Related Quality of Life (HRQoL) as Assessed by the Short Form 36 Health Survey Version 2.0 (SF-36 V2) Acute Form Physical Functioning Domain Score
Time frame: From baseline through Week 48
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Role-Physical Domain Score
Time frame: From baseline through Week 48
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Bodily Pain Domain Score
Time frame: From baseline through Week 48
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form General Health Domain Score
Time frame: From baseline through Week 48
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Vitality Domain Score
Time frame: From baseline through Week 48
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Social Functioning Domain Score
Time frame: From baseline through Week 48
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Role-Emotional Domain Score
Time frame: From baseline through Week 48
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Mental Health Domain Score
Time frame: From baseline through Week 48
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Physical Component Summary Score
Time frame: From baseline through Week 48
Change From Baseline in HRQoL as Assessed by the SF-36 V2 Acute Form Mental Component Summary Score
Time frame: From baseline through Week 48
Change From Baseline in Health Status as Assessed by the EuroQol-5 Dimensions 5-Level (EQ-5D-5L) Score
Time frame: From baseline through Week 48
Time To First Occurrence of Sustained ≥40% Estimated Glomerular Filtration Rate (eGFR) Decline From Baseline, End Stage Kidney Disease (ESKD), or Renal Death
Time frame: From randomization up to 4.2 years
Change From Baseline in Body Weight
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Waist Circumference
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Waist-to-Height Ratio
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Systolic Blood Pressure
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Diastolic Blood Pressure
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Heart Rate
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Double Product
Double product is defined as heart rate multiplied by systolic blood pressure.
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Pulse Pressure
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Mean Arterial Pressure
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Total Cholesterol
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Non-High-Density Lipoprotein (HDL)
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Low-Density Lipoprotein (LDL)
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in HDL
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Triglycerides (TG)
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Very-low-Density Lipoprotein (vLDL)
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in Hemoglobin A1c (HbA1c)
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in High-Sensitivity C-Reactive Protein (hs-CRP)
Time frame: From baseline through the end of study (up to 4.2 years)
Change From Baseline in N-Terminal pro-B-Type Natriuretic Peptide (NT-proBNP)
Time frame: From baseline through the end of study (up to 4.2 years)
No study locations are listed for this record.
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Start is estimated for Jan 2027; primary completion for Mar 2031, 50 months later.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 50 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enicepatide